Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004340178 | SCV004060720 | uncertain significance | not specified | 2023-09-13 | criteria provided, single submitter | clinical testing | The c.7102A>G (p.I2368V) alteration is located in exon 41 (coding exon 40) of the FASN gene. This alteration results from a A to G substitution at nucleotide position 7102, causing the isoleucine (I) at amino acid position 2368 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005104082 | SCV005817818 | uncertain significance | Epileptic encephalopathy | 2024-09-16 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2368 of the FASN protein (p.Ile2368Val). This variant is present in population databases (no rsID available, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with FASN-related conditions. ClinVar contains an entry for this variant (Variation ID: 2595073). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |